1.
J Pediatr Hematol Oncol
; 46(2): e143-e146, 2024 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38237014
RESUMO
Isavuconazonium sulfate (ISA) is a triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis in adults. This single-center, retrospective review of pediatric oncology and stem cell transplant patients receiving ISA for prophylaxis (n=20) or treatment (n=6) of invasive fungal disease (IFD) aims to characterize real-world clinical efficacy and toxicity of ISA in patients <18 years of age. Of 20 patients receiving ISA for prophylaxis, three patients had presumed breakthrough IFD (1 proven, 2 probable/possible). No adverse effects were attributed to ISA use or led to the discontinuation of therapy.
Assuntos
Infecções Fúngicas Invasivas , Neoplasias , Nitrilas , Piridinas , Adulto , Criança , Humanos , Estudos Retrospectivos , Antifúngicos , Infecções Fúngicas Invasivas/tratamento farmacológico , Triazóis , Transplante de Células-Tronco , Neoplasias/tratamento farmacológico
2.
Pediatr Blood Cancer
; 71(4): e30914, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38321590